Skip to main content
Team Jack Foundation - Funding Research for Pediatric Brain Cancer

Follow on    Like on    SHOP   DONATE  

 
 
 

Funding Research for Pediatric Brain Cancer

  • Home
  • About
  • Research
  • Get Involved
    • Fundraise
    • Give
    • Events
    • Become a Sponsor
    • Volunteer
  • Families
 
 

Clinical Trial Finder

Filters

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

You can narrow your results further by searching each trial’s description for a specific word. Keep in mind that this will search the full description. We recommend carefully reviewing each trial information to ensure that it is an appropriate fit for you.

51 - 60 of 2055 Trials
  • A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors

    The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.

    18 Years and Over
    Recruiting
    Learn More
  • ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme

    Assess safety and tolerability of ADI-PEG 20 in combination with radiotherapy and Temozolomide in newly diagnosed GBM

    20 Years - 75 Years
    Recruiting
    Learn More
  • Adjuvant Avelumab in Merkel Cell Cancer

    This randomized phase III trial studies how well avelumab works in treating patients with Merkel cell cancer that has spread to the lymph nodes and have undergone surgery and/or radiation therapy. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    18 Years and Over
    Recruiting
    Learn More
  • Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients

    In this phase I/II trial, the primary objective is to determine overall and progression-free survival of patients with newly diagnosed glioblastoma when autologous Wilms' tumor 1 (WT1) messenger (m)RNA-loaded dendritic cell (DC) vaccination is added to adjuvant temozolomide maintenance treatment following (sub)total resection and temozolomide-based chemoradiation.

    18 Years and Over
    Recruiting
    Learn More
  • Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma

    Stage II patients with primary surgical treatment of cuMM are often at risk for recurrence of their disease. This risk may be reduced by adjuvant systemic treatment. Due to toxicities of adjuvant therapies the aim is to identify patients at high risk for relapse and to administer adjuvant treatment only to these patients. Thus an optimal balance between insufficient treatment vs. overtreatment has to be found. To define these patients a prognostic biomarker test will be used in addition to conventional AJCC staging. AJCC staging takes into account several prognostic factors. However, to subdivide stage II melanoma patients into...

    18 Years - 80 Years
    Recruiting
    Learn More
  • Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma

    This multi-center randomized controlled phase II trial will investigate the impact of stereotactic fractionated radiotherapy to the resection cavity of complete resected recurrent glioblastoma on progression free survival. As secondary endpoints, overall survival, safety and toxicity as well as early response criteria on MRI, quality of life and neurocognitive function will be assessed. Chemotherapy will not be part of the protocol, however, additional treatment will be possible upon investigators best choice.

    18 Years - 99 Years
    Recruiting
    Learn More
  • Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma

    This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.

    18 Years and Over
    Recruiting
    Learn More
  • Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

    The purpose of this study is to assess rate of disease relapse and hazard rate of disease relapse after neoadjuvant therapy based on the statuses of pathologic complete response or non-pathologic complete response, and postoperative adjuvant therapy.

    18 Years and Over
    Recruiting
    Learn More
  • Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

    Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.

    18 Years and Over
    Recruiting
    Learn More
  • Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

    Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation according to histopathological risk factors of the International Retinoblastoma Staging Working Group.

    2 Months - 10 Years
    Recruiting
    Learn More
← Previous 1 2 3 4 5 6 7 8 9 … 206 Next →
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Team Jack Foundation

PO Box 607, Atkinson, NE 68713

For general information

Info@TeamJackFoundation.org

fundraiser information

Kylie@TeamJackFoundation.Org

media inquiries

Info@TeamJackFoundation.Org

other questions call

855-RUN-JACK

      

About

  • About Us
  • Our Focus
  • Team Jack All Stars
  • Jack Hoffman
  • Team Jack News
  • Team Jack Blog
  • Video Gallery
  • Husker Alumni Chapter

Get Involved

  • Fundraise
  • Give
  • Events
  • Become a Sponsor
  • Volunteer

Shop

  • Team Jack Apparel
  • Team Jack Accessories
  • Team Jack All Stars
  • Clearance Rack

Resources

  • CureSearch.org
  • CureTheKids.org
  • Dana-Farber.org

 
 

Join Our Fight!!!

News, events and research delivered to your inbox.

Committed to helping find a cure for pediatric brain cancer.

© Copyright Team Jack Foundation (All Rights Reserved)

Privacy Policy